Skip to content
FDAMedicines

Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) Issues Voluntary Nationwide Recall of Cetirizine Hydrochloride Tablets USP 5 mg Due to Potential Cross Contamination with Ranitidine

FDA recall n-unique-pharmaceutical-laboratories-div-j-b-chemicals-pharmaceuticals-ltd-issues- ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

Check my lot or code

Is yours in this recall?

Type the lot, batch, date code, model number or UPC printed on the product. It is compared here, in your browser, with the codes this notice lists. It stays in this page: it is not added to the address.

General information on recalls from the agency: U.S. Food and Drug Administration (opens in a new tab).

What the agency says to do

FDA’s record gives no instruction for consumers.

Note from Recalls Watch, not agency text

Why it was recalled

Potential cross contamination with Ranitidine
Text from FDA, unedited.

The recalled product

FOR IMMEDIATE RELEASE – July 18th, 2026 – Panoli, Gujarat, Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) is voluntarily recalling four lots of Cetirizine Hydrochloride Tablets USP 5 mg to the consumer level due to cross contamination with Ranitidine.
Text from FDA, unedited.

Company announcement, as FDA publishes it

FOR IMMEDIATE RELEASE – July 18th, 2026 – Panoli, Gujarat, Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) is voluntarily recalling four lots of Cetirizine Hydrochloride Tablets USP 5 mg to the consumer level due to cross contamination with Ranitidine.

Risk Statement: For consumers with a hypersensitivity to the ingredients in ranitidine, there is a reasonable probability that ingestion of Cetirizine tablets contaminated with ranitidine could result in serious adverse events including severe hypersensitivity reactions and anaphylaxis that manifests as hypotension, dyspnea, difficulty swallowing, throat and facial edema, generalized pruritic, urticaria, and loss of consciousness, which are all life-threatening. To date, Unique Pharmaceuticals has not received any reports of adverse events related to this recall.

The product is used as an Antihistamine and is packaged in HDPE Bottle pack of 100 tablets (NDC: 16571-401-10).

Product complaint received that a pharmacy technician identifies the discrepancy while counting the tablets at the time of dispensing. A product complaint reported about Appearance of red dot on Tablets of Cetirizine Hydrochloride Tablets USP 5 mg and some tablets are discolored (Appeared as discolored due to multiple red colored dots on tablets).

The product subject to this recall is listed below and packaged in HDPE bottles. The product can be identified by reviewing the product name, manufacturer details and lot number displayed on the bottle. Product was distributed Nationwide to several wholesalers/retailers.

Unique Pharmaceuticals has notified its distributor Rising Pharma Holdings Inc. (2 Tower Center Blvd., Suite 1401A, East Brunswick, NJ 08816) who has notified its distributors and direct customers by email and is arranging for the return of all recalled products.

Consumers with general or medical inquiries regarding this recall can contact Rising Pharma Holdings Inc. at: Phone number : 1-844-874-7464 8:00 a.m. to 5:00 p.m. (EST), (Monday-Friday) or e-mail address : pv@risingpharma.com or qa@risingpharma.com . Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online : www.fda.gov/medwatch/report.htm 1

Regular Mail or Fax : Download form www.fda.gov/MedWatch/getforms.htm 2 or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Text from FDA (the company’s words), unedited.
  • Cetirizine Hydrochloride Tablets USP 5 mg, Pack 100’s HDPE container

    Lot or code
    NDC: 16571-401-10; Manufacturer: Unique Pharmaceutical ; Laboratories (A Div. of J.; B. Chemicals &; Pharmaceuticals Ltd.); Distributed By: Rising Pharma ; Holdings Inc.; Lot ; Numbers: GY825029; Expiration ; Date: 10/2028 | NDC: 16571-401-10; Manufacturer: Unique Pharmaceutical ; Laboratories (A Div. of J.; B. Chemicals &; Pharmaceuticals Ltd.); Distributed By: Rising Pharma ; Holdings Inc.; Lot ; Numbers: GY825030; Expiration ; Date: 10/2028 | NDC: 16571-401-10; Manufacturer: Unique Pharmaceutical ; Laboratories (A Div. of J.; B. Chemicals &; Pharmaceuticals Ltd.); Distributed By: Rising Pharma ; Holdings Inc.; Lot ; Numbers: GY825031; Expiration ; Date: 10/2028 | NDC: 16571-401-10; Manufacturer: Unique Pharmaceutical ; Laboratories (A Div. of J.; B. Chemicals &; Pharmaceuticals Ltd.); Distributed By: Rising Pharma ; Holdings Inc.; Lot ; Numbers: GY825032; Expiration ; Date: 10/2028

Source

Issued by
U.S. Food and Drug Administration
Firm
Unique Pharmaceutical Laboratories

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Medicine: Cetirizine, Month: July 2026, Week 2026-W29. Browse more medicines recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “Potential cross contamination with Ranitidine”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

How do I know if my product is included?

Compare the lot or code printed on your product with the codes FDA lists on this notice, product by product.

How does the code check on this page work?

You type the lot, batch, date code, model number or UPC from your package and the page compares it, in your browser, with the codes FDA lists on this notice. It reports a match, a possible match (your code is part of a longer listed code) or no match. It only compares text: a notice that describes products by dates, sizes or “all lots” cannot be compared, so “no match” does not clear a product. The comparison runs in your browser and the page does not send the code anywhere, and the code stays out of the page address. Only if you press “Copy link to this result” is a link made that carries it, and whoever opens that link requests that address from this site.

When was this recall published?

FDA published this company announcement on July 18, 2026.